A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine | Zendy

Takahiro Kumode | Zendy; Ayano Fukui | Zendy; Go Eguchi | Zendy; Terufumi Yamaguchi | Zendy; Yasuhiro Maeda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine

Author(s) -

Takahiro Kumode,

Ayano Fukui,

Go Eguchi,

Terufumi Yamaguchi,

Yasuhiro Maeda

Publication year - 2014

Publication title -

case reports in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.2

H-Index - 20

eISSN - 1687-9627

pISSN - 1687-9635

DOI - 10.1155/2014/793928

Subject(s) - medicine , azacitidine , tolerability , myelodysplastic syndromes , myeloid leukemia , leukemia , chemotherapy , oncology , pediatrics , intensive care medicine , adverse effect , bone marrow , biochemistry , gene expression , chemistry , dna methylation , gene

Elderly patients with secondary acute myeloid leukemia (AML) following myelodysplastic syndrome (MDS) are often medically unfit for or resistant to chemotherapy, and their prognosis is dismal. In the present paper, we reported a case of secondary leukemia following MDS in an 80-year-old male patient who was deemed unfit for chemotherapy owing to his old age and poor physical condition. Despite a high tumor burden, treatment with AZA exerted a remarkable response, leading to an immediate cytoreduction in our case. Our results suggest that AZA can be an attractive therapeutic option for elderly MDS or AML patients, offering adequate efficacy and high tolerability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research